PPAR Research

The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer


Status
Published

Lead Editor

1University of Palermo, Palermo, Italy

2University College London, London, UK

3Génomique Fonctionnelle des Tumeurs Solides, Paris, France


The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer

Description

The peroxisome proliferator-activated receptors (PPARs) belong to the ligand-inducible nuclear hormone receptor superfamily including three major members: PPARα (also called NR1C1), PPARβ/δ (also called NR1C2), and PPARγ (also called NR1C3). Despite several similarities, each PPAR isoform shows specific functions likely due to different biochemical properties, variable tissue distribution, and differential responses to different ligands. PPAR transcriptional activity can be modulated through a nongenomic cross-talk with phosphatases and kinases, including ERK1/2, p38-MAPK, PKA, PKC, AMPK, and GSK3. PPARs can form heterodimers with retinoid X receptor (RXR) modulating the expression of genes involved in lipid metabolism, adipogenesis, maintenance of metabolic homeostasis, and inflammation and inducing also anticancer effects in a variety of human tumors. Although all PPAR isoforms are implicated in several metabolic syndromes, PPARγ seems to be mostly involved in tumorigenesis regulation via activation of different pathways. Therefore, the modulation of PPAR signaling pathways could be a potential novel strategy to inhibit carcinogenesis and tumor progression. PPARγ can be activated by natural ligands, such as fatty acids and their derivatives, as well as synthetic ligands, such as thiazolidinediones (TZDs), including ciglitazone, rosiglitazone, troglitazone, and pioglitazone.

TZDs have been shown to be a class of drugs with potent insulin-sensitizing activity used to improve lipid and glucose metabolism in obesity and type 2 diabetes via PPAR. Since accumulating evidence highlighted the role of PPAR signaling in carcinogenesis, type 2 diabetes, and other metabolic disorders, such as obesity, understanding the potential molecular mechanisms underlying the interplay between metabolism, PPAR signaling, and cancer may represent an interesting research field for the development of novel strategies useful for the prevention and treatment of cancer. Since there exists a strong correlation between obesity and diabetes and both have been also shown to increase the cancer risk, the identification of the molecular mechanisms by which PPAR modulates these events may help us to better understand how the diet may affect the cancer susceptibility.

We invite investigators to submit original research articles as well as review articles that aim to increase our knowledge about the correlation between metabolic syndromes and cancer via activation of different PPAR signaling pathways in order to identify novel potential therapeutic targets involved in the development of cancer and cancer-related metabolic syndromes.

Potential topics include but are not limited to the following:

  • Involvement of PPAR signaling pathway in carcinogenesis
  • PPARs and cancer stem cells
  • PPAR ligands as therapeutic agents in several types of cancers
  • Toxicity associated with the exposure to PPAR ligands
  • Nongenomic events induced by PPAR ligands
  • Role of PPARs in different cancer-related metabolic syndromes
  • Role of PPARs in modulating the cancer risk induced by diabetes and obesity

Articles

  • Special Issue
  • - Volume 2017
  • - Article ID 1830626
  • - Editorial

The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer

Daniele Fanale | Valeria Amodeo | Stefano Caruso
  • Special Issue
  • - Volume 2017
  • - Article ID 2865283
  • - Research Article

Fatty Acids of CLA-Enriched Egg Yolks Can Induce Transcriptional Activation of Peroxisome Proliferator-Activated Receptors in MCF-7 Breast Cancer Cells

Aneta A. Koronowicz | Paula Banks | ... | Piotr Laidler
  • Special Issue
  • - Volume 2017
  • - Article ID 4810672
  • - Review Article

Deciphering the Roles of Thiazolidinediones and PPAR in Bladder Cancer

Melody Chiu | Lucien McBeth | ... | Terry D. Hinds
  • Special Issue
  • - Volume 2017
  • - Article ID 8252796
  • - Review Article

PPAR Agonists for the Prevention and Treatment of Lung Cancer

Sowmya P. Lakshmi | Aravind T. Reddy | ... | Raju C. Reddy
  • Special Issue
  • - Volume 2017
  • - Article ID 8187235
  • - Review Article

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway

Laura La Paglia | Angela Listì | ... | Daniele Fanale
  • Special Issue
  • - Volume 2017
  • - Article ID 7058424
  • - Review Article

MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers

Dorothea Portius | Cyril Sobolewski | Michelangelo Foti
  • Special Issue
  • - Volume 2016
  • - Article ID 6517313
  • - Review Article

Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions

Salvatore Giovanni Vitale | Antonio Simone Laganà | ... | Rosario D’Anna
  • Special Issue
  • - Volume 2016
  • - Article ID 7403230
  • - Review Article

PPARs and Mitochondrial Metabolism: From NAFLD to HCC

Tommaso Mello | Maria Materozzi | Andrea Galli
  • Special Issue
  • - Volume 2016
  • - Article ID 3082340
  • - Review Article

PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance

Robert I. Glazer
  • Special Issue
  • - Volume 2016
  • - Article ID 3038164
  • - Review Article

PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs

Serena Vella | Pier Giulio Conaldi | ... | Aldo Pagano
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore7.100
Impact Factor2.953
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.